BACKGROUND: Plasma acyl and des-acyl ghrelin are thought of as components of total ghrelin, but this has never been validated using ex vivo spiking experiments, human sample collection comparisons and fit-for-purpose translatable assays. RESULTS: Acyl ghrelin plasma stability was analyzed by LC-MS/MS and it revealed that acyl ghrelin is enzymatically and chemically converted to des-acyl ghrelin in the presence of active serine proteases and HCl. ELISAs with less than 30% total error were used to assess acyl ghrelin behavior in matched authentic human samples. Acyl and total ghrelin were not statistically different in 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride samples and acyl ghrelin losses in K(2)EDTA plasma were accounted for in des-acyl ghrelin formation. CONCLUSION: Acyl ghrelin is total ghrelin and des-acyl ghrelin should not be detectible in healthy human plasma under optimal sample handling and assaying conditions.
BACKGROUND: Plasma acyl and des-acyl ghrelin are thought of as components of total ghrelin, but this has never been validated using ex vivo spiking experiments, human sample collection comparisons and fit-for-purpose translatable assays. RESULTS:Acyl ghrelin plasma stability was analyzed by LC-MS/MS and it revealed that acyl ghrelin is enzymatically and chemically converted to des-acyl ghrelin in the presence of active serine proteases and HCl. ELISAs with less than 30% total error were used to assess acyl ghrelin behavior in matched authentic human samples. Acyl and total ghrelin were not statistically different in 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride samples and acyl ghrelin losses in K(2)EDTA plasma were accounted for in des-acyl ghrelin formation. CONCLUSION:Acyl ghrelin is total ghrelin and des-acyl ghrelin should not be detectible in healthy human plasma under optimal sample handling and assaying conditions.
Authors: William S Denney; Gabriele E Sonnenberg; Santos Carvajal-Gonzalez; Theresa Tuthill; V Margaret Jackson Journal: Br J Clin Pharmacol Date: 2016-10-29 Impact factor: 4.335
Authors: J Kong; J Chuddy; I A Stock; P M Loria; S V Straub; C Vage; K O Cameron; S K Bhattacharya; K Lapham; K F McClure; Y Zhang; V M Jackson Journal: Br J Pharmacol Date: 2016-03-17 Impact factor: 8.739
Authors: C Tezenas du Montcel; P Duriez; N Lebrun; D Grouselle; B de Grimaudet; R Dardennes; J Epelbaum; M Cuenca; O Viltart; P Gorwood; V Tolle Journal: Compr Psychoneuroendocrinol Date: 2022-05-20
Authors: T D Müller; R Nogueiras; M L Andermann; Z B Andrews; S D Anker; J Argente; R L Batterham; S C Benoit; C Y Bowers; F Broglio; F F Casanueva; D D'Alessio; I Depoortere; A Geliebter; E Ghigo; P A Cole; M Cowley; D E Cummings; A Dagher; S Diano; S L Dickson; C Diéguez; R Granata; H J Grill; K Grove; K M Habegger; K Heppner; M L Heiman; L Holsen; B Holst; A Inui; J O Jansson; H Kirchner; M Korbonits; B Laferrère; C W LeRoux; M Lopez; S Morin; M Nakazato; R Nass; D Perez-Tilve; P T Pfluger; T W Schwartz; R J Seeley; M Sleeman; Y Sun; L Sussel; J Tong; M O Thorner; A J van der Lely; L H T van der Ploeg; J M Zigman; M Kojima; K Kangawa; R G Smith; T Horvath; M H Tschöp Journal: Mol Metab Date: 2015-03-21 Impact factor: 7.422
Authors: Edoardo Vergani; Carmine Bruno; Cesare Gavotti; Luigi Simone Aversa; Maria Martire; Antonio Mancini; Diego Currò Journal: IUBMB Life Date: 2021-05-28 Impact factor: 3.885